Results from the Barostim Therapy for heart failure randomised controlled clinical trial have been accepted by the American College of Cardiology (ACC) for presentation in a Featured Clinical Research Session, according to CVRx. Results will be presented by William Abraham from The Ohio State University, Columbus, USA.
CVRx completed enrolment of the 146-patient clinical trial to determine the performance of Barostim Therapy for patients suffering from chronic heart failure with advanced symptoms. Promising results from an earlier study demonstrating clinical improvement and reduced hospitalisations have already been presented and published. The six-month results from the trial are being prepared for presentation at ACC and for manuscript publication.
Barostim neo is a second generation device that uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat patients suffering from chronic heart failure. The therapy is also a treatment option for patients with resistant hypertension. The system works by electrically activating the baroreceptors, the body’s natural sensors that regulate cardiovascular function. By activating this afferent pathway, Barostim restores sympatho-vagal balance by reducing sympathetic activity and increasing parasympathetic activity.